[HTML][HTML] Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC
S Gao, N Li, S Gao, Q Xue, J Ying, S Wang… - Journal of Thoracic …, 2020 - Elsevier
Introduction Programmed death receptor-1 (PD-1) inhibitors have shown efficacy in first-line
treatment of NSCLC; however, evidence of PD-1 inhibitor as neoadjuvant treatment is …
treatment of NSCLC; however, evidence of PD-1 inhibitor as neoadjuvant treatment is …
Revisiting neoadjuvant therapy in non-small-cell lung cancer
Despite the rapidly evolving treatment landscape in advanced non-small-cell lung cancer
(NSCLC), developments in neoadjuvant and adjuvant treatments have been nascent by …
(NSCLC), developments in neoadjuvant and adjuvant treatments have been nascent by …
[HTML][HTML] PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations
Y Jiang, M Chen, H Nie, Y Yuan - Human vaccines & …, 2019 - Taylor & Francis
ABSTRACT Programmed death-1 (PD-1) is a cell surface receptor that functions as a T cell
checkpoint and plays a central role in regulating T cell exhaustion. Binding of PD-1 to its …
checkpoint and plays a central role in regulating T cell exhaustion. Binding of PD-1 to its …
[HTML][HTML] Radiation dose and fraction in immunotherapy: one-size regimen does not fit all settings, so how does one choose?
Recent evidence indicates that ionizing radiation can enhance immune responses to
tumors. Advances in radiation delivery techniques allow hypofractionated delivery of …
tumors. Advances in radiation delivery techniques allow hypofractionated delivery of …
Recent advances in non-small cell lung cancer targeted therapy; an update review
Lung cancer continues to be the leading cause of cancer-related death worldwide. In the last
decade, significant advancements in the diagnosis and treatment of lung cancer, particularly …
decade, significant advancements in the diagnosis and treatment of lung cancer, particularly …
Squamous cell lung cancer: Current landscape and future therapeutic options
Squamous cell lung cancers (lung squamous cell carcinomas [LUSCs]) are associated with
high mortality and a lack of therapies specific to this disease. Although recurrent molecular …
high mortality and a lack of therapies specific to this disease. Although recurrent molecular …
The complementarity of DDR, nucleic acids and anti-tumour immunity
Immune checkpoint blockade (ICB) immunotherapy is a first-line treatment for selected
cancers, yet the mechanisms of its efficacy remain incompletely understood. Furthermore …
cancers, yet the mechanisms of its efficacy remain incompletely understood. Furthermore …
Inhibitors of immune checkpoints—PD-1, PD-L1, CTLA-4—new opportunities for cancer patients and a new challenge for internists and general practitioners
MZ Wojtukiewicz, MM Rek, K Karpowicz… - Cancer and Metastasis …, 2021 - Springer
The treatment of cancer patients with immune checkpoint inhibitors (ICI)(anti-CTLA-4, anti-
PD-1, anti-PD-L1, combined therapy anti-PD-1/PD-L1 with anti-CTLA-4) has without doubt …
PD-1, anti-PD-L1, combined therapy anti-PD-1/PD-L1 with anti-CTLA-4) has without doubt …
Radiotherapy toxicity
D De Ruysscher, G Niedermann, NG Burnet… - Nature Reviews …, 2019 - nature.com
Radiotherapy is used in> 50% of patients with cancer, both for curative and palliative
purposes. Radiotherapy uses ionizing radiation to target and kill tumour tissue, but normal …
purposes. Radiotherapy uses ionizing radiation to target and kill tumour tissue, but normal …
Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment
Immune checkpoint inhibitors (ICIs) have revolutionized the clinical management of multiple
tumours. However, only a few patients respond to ICIs, which has generated considerable …
tumours. However, only a few patients respond to ICIs, which has generated considerable …